Hypericin has excellent photosensitizing properties and displays favorable tumouritropic characteristics, but at the same time exhibits minimal dark toxicity. As such, the compound is a promising photosensitizer in the context of clinical photodynamic therapy (PDT). The present study was undertaken to investigate whether a newly-synthesized series of hypericin derivatives with a bathochromic shift shows promise for future PDT applications. Potentially these structures offer an advantage over the parent compound by being photo-activated by red light, which penetrates deeper into tumour tissue. Our results show that 3 compounds (a dibenzoxazole, a pyridazinone, and especially a dibenzthiazole derivative of hypericin), designed to exhibit a bathochromic shift in their absorption spectrum, demonstrated an efficient singlet oxygen yield and intracellular uptake, and concomitantly a potent photocytotoxic effect under white-light conditions. These results indicate that it is possible to synthesize bathochromically-shifted compounds based on hypericin chemistry which maintain their PDT potential. However, the data also show that the present derivatives are only poor photosensitizers when used under red-light conditions.